Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 23 March, 2020

JPMorgan Asset Mngt

AbbVie Inc. 8.3

RNS Number : 2043H
JPMorgan Asset Management
23 March 2020
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Companydealtin

AbbVie Inc.

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.01 common stock

Date of dealing

20 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)


Long

Short


Number


(%)

Number


(%)

(1)Relevantsecurities

20,200,137*  1.37*

3,126  0.00

(2) Derivatives (other than options)

15,347  0.00

 305,276  0.02

(3)Optionsandagreementstopurchase/sell



Total

20,215,484*  1.37*

308,402  0.02

 

*In addition to the dealings in section 2a, there is an increase in the holding of 18 common stock due to a transfer.

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short


Number


(%)

Number


(%)

(1)Relevantsecurities



 

(2) Derivatives (other than options)



 

(3)Optionsandagreementstopurchase/sell



Total




Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

 

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

231

5

63

7,333

175

44

13,100

3

31

384

116

13,500

93,936

13,928

190

241

69,323

 

12

42

92

1,060

80

28

4,776

232

8,475

8,662

973

4

144

3,313

1

8,913

5,053

128

66.9700 USD

67.6300 USD

67.6370 USD

67.6380 USD

67.6390 USD

67.6400 USD

67.7262 USD

67.9900 USD

67.9920 USD

68.2209 USD

68.4350 USD

68.4866 USD

68.6624 USD

68.8200 USD

69.0968 USD

69.3287 USD

71.6618 USD

 

66.9100 USD

66.9150 USD

66.9170 USD

66.9180 USD

66.9190 USD

66.9200 USD

67.4383 USD

67.4541 USD

67.6592 USD

68.2712 USD

68.3449 USD

68.6850 USD

68.8200 USD

69.3409 USD

69.5800 USD

69.6968 USD

71.6180 USD

71.9017 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)





 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)








 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)




 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)





Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Contact name

Daniel Swart

Telephone number

0207 134 6168

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

Allergan plc

If aconnectedEFM,statenatureofconnection (Note 10)

Financial Advisor to Allergan plc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFIFVLIVFII

a d v e r t i s e m e n t